Introduction: Sudden cardiac death (SCD) of young athletes during competition or training is a tragic event. The long QT syndrome (LQTS) is an arrythmogenic disorder characterized by prolonged ventricular repolarization leading to torsade de pointes evident at electrocardiogram (ECG). Implantable cardioverter defibrillator is an option to revert ventricular fibrillation to sinus rhythm, although the implantation may result in denial of sports participations to the athlete. The authors reviewed the current literature on LQTS in young athletes, to clarify the role of different screening technologies to prevent SCD.
Introduction
Sudden cardiac death (SCD) of young individuals, with no sign of previous disease, is a tragic event. SCD occurring in young athletes during competition or in training is even worse, as athletes are regarded as representative of the healthiest segments of society. Even elite athletes reaching the highest level of physical performance may suffer from serious cardiac disorders without any symptoms or impairment in physical performance. 1 The causes of SCD can be divided into acquired and genetic. The first group includes myocarditis and coronary artery diseases. Genetic caused can, in turn, induce structural diseases, which include arrhythmogenic right ventricular tachycardia and hypertrophic cardiomyopathy, and arrhythmogenic disorders such as Brugada syndrome (BrS), catecholaminergic polymorphic ventricular tachycardia, and long QT syndrome (LQTS). 2 Cardiomyopathies are the most common causes of SCD, 3 but it is not true that patients at high risk of SCD cannot be appropriately identified and managed by cardiovascular (CV) screening and genetic testing. 4 On the other hand, early detection of CV disorders in athletes is justified and can save lives. LQTS is an arrythmogenic disorder characterized by prolonged ventricular repolarization leading to torsades de point 5, 6 on electrocardiogram (ECG). The correct QT interval (QTc) is used for diagnostic purposes (<450 ms in men and <470 ms in women to declare the patient healthy): the greater the length of the QT interval, the higher the risk of ventricular fibrillation. Therefore, LQTS is definitely a cause of SCD. LQTS can be acquired (because of medications, bradycardia, changes in metabolism, electrolyte imbalance), or inborn, the latter with a similar prevalence as BrS. 3 According to USA data, mortality by this syndrome is 2% in athletes, 7 and the diagnosis can be complicated by the variation of the heart rhythm produced by exercise. At present, the diagnosis of LQTS remains clinical, and is based on family history of symptoms, and on rest and exercise ECGs, 8 even though 25-35% of individual with the relevant LQTS genetic make-up may exhibit a normal QT interval at ECG. 9, 10 This review investigates the role of genetic testing and CV screening in this syndrome to decrease the risk of SCD.
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Material and Methods
A systematic review of the literature was performed applying the PRISMA guidelines according to the PRISMA checklist and algorithm 12 ( Fig. 1) . A comprehensive search of PubMed, Medline, CINAHL, Cochrane, Embase and Google Scholar databases was performed using various combinations of the keywords 'QT', 'syndrome', 'screening', 'young', 'athletes', 'genetic', 'electrocardiogram' 'echocardiography' and 'prevention' since inception of the databases. Three independent reviewers separately conducted the search. All journals were considered, and all relevant studies were analyzed. To qualify for the study, an article had to be published in a peer-reviewed journal. All articles were initially screened for relevance by title and abstract, excluding articles without an abstract, and obtaining the full-text article if the abstract did not allow the investigators to assess the defined inclusion and exclusion criteria. The three investigators separately reviewed the abstract of each publication. They then performed a close reading of all papers and extracted data, to minimize selection bias and errors. A cross-reference search of the selected articles was also performed to obtain other relevant articles for the study. All articles reporting screening programs to prevent SCD due to QT-syndrome in athletes were taken into account.
According to the Oxford centre of Evidencebased Medicine, level III-IV articles were found in the literature and included in our study. Given the linguistic capabilities of the authors, articles in English, French, Spanish, German and Italian were included. We included articles published from inception of each database to April 20, 2018 . Inclusion criteria for this review required that: (1) the study reported on the outcomes of CV screening for SCD from LQTS in athletes using history, physical exam, ECG and genetic testing; (2) the history questions and physical exam were based on the American Heart Association (AHA) recommendations or similar guidelines; (3) a sufficiently detailed description of the results of the genetic test(s) used for the screening and (4) ECGs were interpreted using modern standards defined as criteria attempting to account for the physiological changes of training in the athletic heart and genetic test. Missing data pertinent to these parameters warranted exclusion from this systematic review. Literature reviews, case reports, studies in vitro, technical notes, letters to editors and instructional course materials were also excluded. Finally, to avoid bias, the selected articles, the list of references, and the articles excluded from the study were reviewed, assessed and discussed by all the authors. If there was disagreement among investigators regarding the inclusion and exclusion criteria, the senior investigator made the final decision.
No meta-analysis was performed given the insufficient data available from the literature. Therefore, we have analyzed the studies to highlight the current knowledge on this topic.
Results
The literature search and cross-referencing resulted in a total of 53 references, of which 41 were rejected as the abstracts were off topic and/or failed to fulfill the inclusion criteria (Fig. 1) .
After reading the remaining full-text articles, an additional six articles were excluded because of insufficient details and uncertain diagnosis and outcome measures.
Finally, six studies [13] [14] [15] [16] [17] [18] reporting screening programs to prevent SCD from LQTS in young athletes were included. A total of 6400 young athletes screened for SCD were included, with an average age of 18.5 years ranging from 12 13 to 35 13, 18 (Table 1) . The rate of patients affected by a QT-syndrome was 0.4% (28/ 6400). The duration of the QT tract ranged from 460 to 570 ms. Clinical history or physical exams and genetic test were negative in 42% (4/7) and 50% (2/4) of subjects with LQTS.
Discussion
Even Olympic athletes may present complex ventricular tachyarrhythmias, such as LQTS (0.4%).
1
The risk of SCD is not the same in all young athletes with by LQTS because the phenotype is influenced by genotype, polymorphism, mutations, age, sex and management. 8 Prolongation of the QT interval on the ECG in subjects with LQTS can be congenital or acquired. For congenital LQTS, the incidence of which in the general population is estimated at 1 in 2500, 19~1 7 known LQTS-susceptibility genes have been identified. Genetic sequence analysis has identified mutations in seven genes as responsible for LQTS. Three major gene mutations 20 are involved in most instances: 90% of LQTS patients have defects in KCNQ1, KCNH2 and SCN5A, 21 while the rest present mutation of KCNE2, CAV3, SCN4B, SNTA1 and other LQTS-related genes. Patients who present variation in SNC5A suffer from LQT3, and they present with a gain-of-function in Na + channel subunits. 22 Individuals with variation in KCNQ1
and KCNH2 are classified, respectively, as having LQT1 and LQT2, with loss-of-function of different types of K + channels.
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LQT1 is the most common (30-35%) of all LQTS subtypes, 23 and it is associated with a missense mutation or small insertions/deletions 24 on KCNQ1. This gene encodes the α-subunit of the potassium channel responsible for the slow/delayed rectifying potassium (IKs) current, and therefore impacting on ventricular myocyte repolarization. When this channel is defective, a prolonged QT interval is evident. In 392 patients with LQT1, exercise acted as a trigger in 62% of the events, and these patients experienced symptoms earlier than patients with other forms of LQTS.
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LQT2 syndromes from homozygous mutations in KCNH2 are extremely rare in humans, because they are generally not compatible with life. In heterozygous mutations, around 500 mutations in KCNH2 have been identified in association with LQT2. 26 The KCNH2 gene encodes human ether-a-go-go related gene (hERG) the α-subunit of the delayed rapid rectifier potassium channel responsible for conducting Ikr. Sudden auditory stimuli release catecholamines, which produce early after depolarization, and may be the main trigger which occurred in 43% of LQT2 patients with cardiac events. 27, 28 LQT3 syndromes are associated with gain-offunction mutations in the cardiac voltage-gated Na + channel. The impaired Na + channel inactivation brings to depolarizing current prolonging the action potential characterized by depolarization of the cardiomyocyte. 29 Acquired LQTS is more common than the congenital form. 30 Generally, the acquired forms of this arrythmogenic disorder are linked to QT-prolonging drugs, electrolyte disturbances, bradyarrhythmias, myocardial stunning, oxidation of hERG potassium channels or also structural heart disease, metabolic and endocrine abnormalities and sex hormones which are able to modulate QT interval. 4 The ability to distinguish between acquired and congenital LQTS has critical importance to inform subsequent management strategies and prognosis, and it is possible only by means of ECG screening and genetic testing.
An analysis of 647 individuals with types 1, 2 and 3 LQTS showed that cardiac events were highest in the LQT2 (46%) and LQT3 genotypes (42%). 19 The LQT1 genotypes had the lowest event rate at 30%. Furthermore, individuals with a QTc > 500 ms in the LQT1 and LQT2 genotypes had higher event rates. The risk of cardiac events was higher for females in LQT2 and for males in LQT3. 31 A study of 1861 genotype-positive patients found that the QTc interval distribution ranged from 350 to 800 ms with a mean of 450 ± 56 ms, and overall about 25% were within the normal range. These patients with a QTc interval within the normal range had a lower risk (72%) of SCD; nevertheless, they still had a much higher risk than their genotypenegative family members. 8, 32 In a series of 2352 Olympic athletes (from Athens 2004 to Sochi 2014), a long QT interval was suspected in a female judo player, with a QTc of 0.48 s, with negative gene analysis. LQT1 was confirmed by the presence of a mutation in KCNQ1 in an openwater male swimmer, with a QTc interval of 0.47 s, increasing during effort and recovery (0.48 s). 1 Studies on heart rate 33, 34 suggest that, if the vagal tone increases following exercise training, it could increase the risk of arrhythmia in individuals with an LQT1 genotype. 
Age and gender
According to the International LQTS Registry, the risk of an LQTS-triggered cardiac event ranges from 0.5% to 10% per year, but in children who had no history of syncope and a QTc < 500 ms this risk actually decreases. 35, 36 The risk depends on the gender, and, even though females with LQTS, in general, have a longer QTc interval, males have a higher overall risk for cardiac events. When compared with men, women exhibit a longer QTc interval in response to drugs that block the IKr current facilitating the development of torsades de pointes in women. 37 Among the 842 athletes with autopsy-confirmed CV diagnoses, the incidence in males exceeded that in females by 6.5-fold (1:121; 691 vs. 1:787,392 athlete-years; P ≤ 0.001), and the LQTS is present in 7% of male vs. 1.5% in female athletes (P ≤ 0.002). 17 However, gender-related differences cannot be applied to all LQTS types. From the above-cited study of 647 patients with known genotype, there were no gender-related differences in the annual incidence of cardiac arrest or SCD (0.28% in female vs. 0.33% in male patients, P = 0.18) in individuals with LQT1. However, an association with gender has been evidenced in patients with LQT2 and LQT3: in LQT2, females exhibit a greater annual incidence of cardiac arrest or sudden death (0.82 vs. 0.46% in males, P = 0.02), and LQT3 males carried a higher risk (0.96%) than female (0.3%, P = 0.048). 27, 31 Gender and age influenced the probability of SCD in particular cases and types of LQTS, even though the higher incidence of SCD depends on the LQT-genotype and the kind of sport as a trigger of cardiac events.
Athletes
LQTS can cause tragic events leading to SCD, in 1 347 elite athletes in Denmark, but only one athlete (0.2%) suffered from LQTS. 18 Not all subjects with LQTS should be denied sports participation, and therefore athletes with LQTS can, at present, continue their sports. In a series of 353 patients, 157 of which were athletes, between 6 and 40 years of age with genetically confirmed LQTS seen at the Mayo Clinic, 27 (17%) chose, after appropriate evaluation, to interrupt their athletic career, while 130 (83%) decided to continue with sports participation. 35 Athletes with LQTS may choose to continue in competitive sports and can self-disqualify. These disqualifications are justified because most of the lethal LQT1 events (68%) are associated with exercise. No subject with LQT2 and only 4% of the subjects with a LQT3 genotype experienced cardiac arrest after physical exertion. 27 Also, the type of exercise may influence the risk of SCD. Facial immersion in cold water, as in swimming, prolongs the QT interval, and therefore may trigger cardiac events in nearly 15% of children and young adults with LQTS, especially LQT1. 27,38 LQT2 patients should avoid sudden loud noises, such as the starter's pistol in track and field events.
The debate around ECG screening
In cases of SCD, when a heart condition is suspected, family screening should be undertaken. The choice of the screening modality depends on the condition suspected, but it should include clinical history, physical examination and ECG, 39, 40 which is too often presented as a binary 'all or none' response. 11 However,
for those who believe in early detection, screening by history and physical examination alone is not enough (Table 1) . Recent studies of CV screening in American college athletes showed that lethal CV diseases have been discovered performing ECG. However, to be successful, ECG screening programs need accurate interpretation and skilled cardiology resources to evaluate ECG findings. When ECGs are performed with care, approximately one in six abnormal ECGs will represent a relevant cardiac disorder at elevated risk of SCD. 39, 40 There are no specific ECGs features to accurately identify LQTS, and the diagnosis of this syndrome based on absolute QT interval cutoffs cannot be accurate, even though the wave pattern on the ECG suggests important features. LQTS syncope arises from torsades de pointes, and the deaths are from ventricular fibrillation. 38 Almost 40% of LQTS patients do not show a prolonged QTc interval at ECG; therefore, evaluation with exercise ECG often uncovers this syndrome, in particular LQT1. In asymptomatic athletes, the prevalence of QT prolongation was recently reported as 1 in 286 subjects, 15 and, even though an incorrect QT interval characterized all LQTS, physicians can recognize LQT2 from a classic notched or 'bifid' T-wave. Detecting underlying cardiac disease using ECG may lead to institution of life-saving therapies such as ICDs. In a series of 484 children and adolescents, sport pre-participation examinations based on physical examination, 12-Lead ECG and health history were performed. None of the athletes exhibited a QTc interval>500 ms, and borderline QT prolongation was identified in 6.65%. 41 When the evaluation of QT intervals are borderline or when clinical history is equivocal, genetic testing should be undertaken, especially because, after knowing the results of ECG, patients and families could have a false sense of security underestimating the risk of SCD.
Role of genetic testing
Since the first discovery of inheritable monogenic cardiovascular disease (CVD) genes in 1990 and the first complete human genome sequences in 2001, 42, 43 genetic testing impact the diagnosis, risk stratification, and clinical management of patients with CVDs. However, the clinical utility of genetic testing depends on the probability of disease and disease-specific genetic test performance. In individuals with unconvincing phenotypes, the risk of encountering false positives is increased. For this reason, genetic testing should be undertaken only if considerable suspicion for a genetic CVD remains after a previous ECG screening and cardiology investigation. 44 In cardiomyopathies, predisposition to CVDs can be identified using commercially available pancardiomyopathy gene panels. Given the many genetic variants in cardiomyopathy-susceptibility genes (not all of which are causes of CVD), investigating family members remains the best detection method for all inherited cardiomyopathies. In such cases, genetic testing may guide the choice of management, but no intervention has been proven to modify the natural history of in cardiomyopathies, and this may limit their clinical utility.
Cardiac channelopathies are generally characterized by defects in cardiac ion channel macromolecular complexes critical for the distribution of intracellular calcium, but structurally the heart of these patients is normal even though they are predisposed to arrhythmic syncope and SCD. Similar to cardiomyopathies, great caution is recommended using genetic testing, because not each genetic variant is associated with a clinical condition. Remarkably, however, evidence of the utility of genetic testing has been found in LQTS. 45 The relevant genotypephenotype correlations 46 makes this syndrome representative of the few monogenic CVDs in which genetic testing facilitates a genomic/genetic guided approach to both risk stratification and treatment. 44 Molecular genetic screening can reveal underlying mutations to a variable degree among the cardiac ion channel diseases, and in LQTS it can identify 70% of affected individuals 47 ( Table 2 ).
The cost of the analysis is still a limitation, but in conjunction with at rest and exercise ECG, genetic testing is a reliable avenue to investigate these pathologies and mitigate the risk of SCD.
Guidelines for athletes
The Bethesda Conference Guidelines in 2005 were very restrictive, recommending that all previously symptomatic LQTS patients or those with ECG manifestations, especially for athletes with ICDs be restricted to class IA sports that include billiards, bowling, cricket, curling and golf. 3 These guidelines have been applied to males who record a QTc exceeding 470 ms and to females who show QTc > 480 ms. 48 Sympathetic stimulation may be proarrhythmic for individuals with LQTS, and therefore guidelines this prohibitive were justified.
In the same year, the European Society of Cardiology (ESC) published guidelines for athletes more prohibitive than the Bethesda ones. The ESC denied any form of sport to all patients with a diagnosis with LQTS, even if they were phenotypenegative. 48 In athletes who had experienced sudden cardiac arrest or episodes of syncope, the only exercise with low static and dynamic demand was allowed. However, the risk of SCD is not the same among all young athletes with LQTS, and for that reason the guidelines not be so restrictively severe.
The 2013 European Heart Rhythm Association (EHRA), Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS) guidelines, aware of the previously rigid recommendations, stated that athletes with LQTS who wish to continue to participate in their sport should be evaluated by an LQTS expert. With no evidence in the literature that genotype-positive patients without phenotypic manifestations would experience cardiac events during sports, the HRS, EHRA and APHRS ESC guidelines were modified. 48 After a series of data supporting the decrease of SCD incidence in athletes, 3 the AHA/ACC (American Heart Association/American College of Cardiology) Scientific Statement in 2015 mitigates previous guidelines. Individuals who survived a cardiac arrest or had experienced a syncope cannot take part in competitive sports; for those without symptoms, participation in low-intensity sports was allowed, and individuals who are genotype positive but phenotype-negative can compete in all sports without limits. 7 Furthermore, athletes with an ICD may participate in sports if they have been no shocks for 3 months. 3 Many athletes were disqualified from competitive sports, and data do support this approach, including the annual decrease of SCD incidence by 89%, 3.6/100 000 to 0.4/100 000 person-years. 49 Therefore, the AHA categorized the eligibility of LQTS (and other arrhythmogenic conditions) patients to different sports activities with a five-step grading scale (for example, tennis is strongly discouraged, while skating is permitted), but this subdivision may appear confusing in an already complex field. Only appropriate knowledge of the exact molecular triggers that produce torsades de pointes, QT-prolongation and cardiac events can properly outline guidelines avoiding life-threatening episodes; this will only be possible by genetic testing and CV screening.
Conclusion
SCDs in young athletes are clearly tragic events, but with accurate detection programs, it can be possible to mitigate the risk that they happen and to individualize management. For those who are not confident in these methods of investigation, the potential of ECG screening and genetic testing are not well harnessed, but screening programmes reduce the incidence of SCD and they are essential to promote health and safety of young athletes during sport. Even though CV screening remains obligatory in high-risk athletes until otherwise demonstrated, preventing SCD in athletes should be a key point which guides more effective screening for at-risk athletes. Exercise and at rest ECGs are diagnostic in ion channel diseases, especially if in conjunction with molecular genetic screening: both can clarify some of the underlying arrhythmic mechanisms preventing life-threatening events. For a physician avoiding a sudden death is always a satisfying success, but for an elite athlete interrupting their sporting career is a major negative event. The development of these screening technologies can accurately individualize CV diseases and manage the risk of SCD. Blanket exclusion from all sports participation should be considered unnecessary.
